David A. Tuveson
大卫·图韦森
MD, PhD
Director, Lustgarten Foundation Pancreatic Cancer Research Laboratory; Roy J. Zuckerberg Professor of Cancer Research勒斯特加滕基金会胰腺癌研究实验室主任；祖克伯格癌症研究教授
👥Biography 个人简介
Cancer biologist who developed patient-derived pancreatic cancer organoids as a platform to study the desmoplastic, immune-excluded tumor microenvironment. His work illuminates why pancreatic cancer resists checkpoint immunotherapy and identifies stromal and myeloid cell targets for combination strategies to restore immune infiltration.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Pancreatic Cancer Organoid Platform
Established patient-derived pancreatic ductal adenocarcinoma organoids that faithfully recapitulate tumor heterogeneity and microenvironment biology, enabling drug screening and mechanistic study of checkpoint resistance in a human-relevant system.
Desmoplastic Stroma as an Immune Barrier
Defined how activated pancreatic stellate cells and cancer-associated fibroblasts create a physical and biochemical barrier to T cell infiltration, identifying FAK and Hedgehog pathway inhibition as strategies to normalize the stroma and enhance immunotherapy.
Myeloid Cell Reprogramming in Immune Exclusion
Characterized tumor-associated macrophage and myeloid-derived suppressor cell states driving immune exclusion in pancreatic cancer, revealing CSF1R and CXCR2 targeting as approaches to reprogram the myeloid TME and sensitize tumors to checkpoint blockade.
Representative Works 代表性著作
Organoid Models of Human and Mouse Ductal Pancreatic Cancer
Cell (2015)
Established pancreatic cancer organoid systems from mouse and human tumors, enabling functional genomics and drug screening in a 3D model recapitulating in vivo tumor biology.
FAK Depletion Overcomes Residual Resistance in Pancreatic Cancer to Checkpoint Immunotherapy
Nature (2018)
Demonstrated that FAK inhibition reduces desmoplastic stroma and myeloid suppressive cells, enabling T cell infiltration and synergy with PD-1/CTLA-4 checkpoint blockade in pancreatic cancer.
Heterotypic CAF-Tumor Spheroids Promote Early Fibrosis and Immunosuppression by Cluster of Differentiation 8+ T Cells
Cancer Discovery (2021)
Revealed how cancer-associated fibroblast subtypes cooperate with tumor cells to establish immune exclusion and identified subtype-specific targets for stromal normalization.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 大卫·图韦森 的研究动态
Follow David A. Tuveson's research updates
留下邮箱，当我们发布与 David A. Tuveson（Cold Spring Harbor Laboratory）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment